ReviewDrug discovery today2010
Developments towards antiviral therapies against enterovirus 71.
Review in Drug discovery today, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 87 citations in OpenAlex.
- Trial
- The possible role of ursolic acid in Covid-19: A real game changer.Clinical nutrition ESPEN · 2022Article
- Covalent Antiviral Agents.Advances in experimental medicine and biology · 2021Review
- Antiviral potential of natural products from marine microbes.European journal of medicinal chemistry · 2020Review
- The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses.Journal of virology · 2020Article
- A method for hand-foot-mouth disease prediction using GeoDetector and LSTM model in Guangxi, China.Scientific reports · 2019Article
- Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway.Scientific reports · 2019Article
- Hsp27 Responds to and Facilitates Enterovirus A71 Replication by Enhancing Viral Internal Ribosome Entry Site-Mediated Translation.Journal of virology · 2019Article
- Recent Progress on Functional Genomics Research of Enterovirus 71.Virologica Sinica · 2019Review
- A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs.Emerging microbes & infections · 2019Article
- Artemisia capillaris inhibited enterovirus 71-induced cell injury by preventing viral internalization.The Kaohsiung journal of medical sciences · 2018Article
- Human genome-wide RNAi screen reveals host factors required for enterovirus 71 replication.Nature communications · 2016Article
- Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.Scientific reports · 2016Article
- ATP1B3: a virus-induced host factor against EV71 replication by up-regulating the production of type-I interferons.Virology · 2016Article
- Antiviral activity of micafungin against enterovirus 71.Virology journal · 2016Article
- Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein.Journal of biomedical research · 2016Article
- Article
- Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses.Antimicrobial agents and chemotherapy · 2015Article
- Anti-Enterovirus 71 Agents of Natural Products.Molecules (Basel, Switzerland) · 2015Review
- Potential Antiviral Agents from Marine Fungi: An Overview.Marine drugs · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus 71 (EV71) has emerged as a clinically important neurotropic virus that can cause acute flaccid paralysis and encephalitis, leading to cardiopulmonary failure and death. Recurring outbreaks of EV71 have been reported in several countries. The current lack of approved anti-EV71 therapy has prompted intense research into antiviral development. Several strategies--ranging from target-based chemical design to compound library screenings--have been employed, while others revisited compound series generated from antiviral developments against poliovirus and human rhinoviruses. These efforts have given rise to a diversity of antiviral candidates that include small molecules and non-conventional nucleic-acid-based strategies. This review aims to highlight candidates with potential for further clinical development based on their putative modes of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.